山东大学学报(医学版) ›› 2014, Vol. 52 ›› Issue (7): 50-55.doi: 10.6040/j.issn.1671-7554.0.2014.002
张诤, 申洪昌, 付国斌, 张建超, 王潍博
ZHANG Zheng, SHEN Hongchang, FU Guobin, ZHANG Jianchao, WANG Weibo
摘要: 目的 通过检测G蛋白偶联受体激酶6(G protein coupled receptor kinase 6, GRK6)在胃癌中的表达情况,探讨其与相关临床病理参数及生存预后的关系。方法 通过组织芯片及免疫组化技术,检测132例胃恶性肿瘤及8例胃良性疾病中GRK6 的表达情况,统计学分析影响GRK6表达情况的相关因素,并根据相关随访资料,探讨GRK6表达与患者预后的关系。结果 GRK6在120例胃恶性肿瘤中高表达率为49.17%,低表达率为50.83%,多因素Logistic回归分析表明GRK6的表达与肿瘤分化相关(P<0.05)。GRK6高表达患者的5年存活率为28.81%,低表达者的5年存活率为67.21%,差异有统计学意义(P<0.05)。Cox生存预后分析提示GRK6的表达及术后有无治疗为影响胃癌患者预后的独立因素(P<0.05)。结论 GRK6在胃腺癌中的表达程度与肿瘤的分化情况密切相关,高表达者的5年生存率明显低于低表达者,为胃癌患者的不良预后指标,可能在胃癌发生发展中起重要作用。
中图分类号:
[1] Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008[J]. CA Cancer J Clin, 2008, 58(4):71-96. [2] Roder D M, Kelley J R, Duggan J M. Gastric cancer epidemiology and risk factors[J]. J Clin Epidemiol, 2003, 56(1):1-9. [3] Pitcher J A, Freedman N J, Lefkowitz R J. G protein-coupled receptor kinases[J]. Annurev Biochem, 1998, 67(1):653-692. [4] Premont R T. Once and future signaling:G protein-coupled receptor kinase control of neuronal sensitivity[J]. Neuromolecular Med, 2005, 7(1-2):129-147. [5] Claing A, Laporte S A, Caron M G, et al. Endocytosis of G protein-coupled receptors:roles of G protein-coupled receptor kinases and beta-arrestin proteins[J]. Prog Neurobiol, 2002, 66(2):61-79. [6] Lymperopoulos A, Bathgate A. Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins:the known and the unknown[J]. Pharmacogenomics, 2012, 13(3):323-341. [7] Raghuwanshi S K, Smith N, Rivers E J, et al. G protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression, and metastasis[J]. J Immunol, 2013, 190(10):5329-5336. [8] Tiedemann R E, Zhu Y X, Schmidt J, et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6[J]. Blood, 2010, 115(8):1594-1604. [9] Li Y P. GRK6 expression in patients with hepatocellular carcinoma[J]. Asian Pac J Trop Med, 2013, 6(3):220-223. [10] Kononen J, Bubendortf L, Kallioniemi A, et al. Tissue microarrays for high through put molecular profiling of tumor specimens[J]. Nat Med, 1998, 4(7):844-847. [11] Métayé T, Gibelin H, Perdrisot R, et al. Pathophysiological roles of G-protein-coupled receptor kinases[J]. Cell Signal, 2005, 17(8):917-928. [12] Hupfeld C J, Olefsky J M. Regulation of receptor tyrosine kinase signaling by GRKs and beta-arrestins[J]. Annu Rev Physiol, 2007, 69:561-577. [13] Cipolletta E, Campanile A, Santulli G, et al. The G protein coupled receptor kinase 2 plays an essential role in beta-adrenergic receptor-induced insulin resistance[J]. Cardiovasc Res, 2009, 84(3):407-415. [14] Penela P, Murga C, Ribas C, et al. The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets[J]. Br J Pharmacol, 2010, 160(4):821-832. [15] Martini J S, Raake P, Vinge L E, et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes[J]. Proc Natl Acad Sci USA, 2008, 105(34) :12457-12462. [16] Woerner B M, Luo J, Brown K R, et al. Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth[J]. Mol Cancer Res, 2012, 10(1):156-166. [17] Métayé T, Menet E, Guilhot J, et al. Expression and activity of G protein-coupled receptor kinases in differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 2002, 87(7):3279-3286. [18] Kim J I, Chakraborty P, Wang Z, et al. G-protein coupled receptor kinase 5 regulates prostate tumor growth[J]. J Urol, 2012, 187(1):322-329. [19] Wu C C, Tsai F M, Shyu R Y, et al. G protein-coupled receptor kinase 5 mediates Tazarotene-induced gene 1-induced growth suppression of human colon cancer cells[J]. BMC Cancer, 2011, 11:175. doi:10.1186/1471-2407-11-175. [20] Wei Z, Hurtt R, Ciccarelli M, et al. Growth inhibition of human hepatocellular carcinoma cells by overexpression of G protein-coupled receptor kinase2[J]. J Cell Physiol, 2012, 227(6):2371-2377. |
[1] | 底学敏,牛书雷,赵静,杜随,于慧敏,张宏涛,王娟. CT引导下125I粒子植入治疗晚期胃癌淋巴结转移[J]. 山东大学学报(医学版), 2017, 55(9): 79-84. |
[2] | 聂思月,王震,孙靖宇,刘杰,李娟,魏小娟,路春晓,吕兴龑,王淑云,孙玉萍. ANGPTL5在人胃癌组织中的表达及临床意义[J]. 山东大学学报(医学版), 2017, 55(8): 61-65. |
[3] | 贾振军, 曲勇, 张世杰. HER2和p53在胃腺癌不同衍变阶段中的表达及意义[J]. 山东大学学报(医学版), 2015, 53(3): 73-76. |
[4] | 丁娟, 郑桂喜, 杜鲁涛, 尹作花, 张建, 王传新. 外周血sHLA-G与PGR、GPR联合检测在胃癌诊断中的效能评估[J]. 山东大学学报(医学版), 2015, 53(11): 59-63. |
[5] | 徐翠, 王涛, 周平. 儿童幽门螺杆菌免疫组化染色检测分析[J]. 山东大学学报(医学版), 2014, 52(9): 81-84. |
[6] | 许加军, 刘宗现, 许风雷, 王磊, 孔维华. 自噬相关蛋白4EBP1与eIF4E在几种常见脑瘤组织中的表达[J]. 山东大学学报(医学版), 2014, 52(9): 72-76. |
[7] | 李玲, 王丽丽, 王胜江, 于超, 刘延鹏, 徐成伟. 乳腺癌患者血浆D-二聚体水平与预后关系的探讨[J]. 山东大学学报(医学版), 2014, 52(9): 77-80. |
[8] | 连海峰, 李明, 刘成霞, 贾兴芳, 李丹. NRP2在胃癌中的表达及其临床意义[J]. 山东大学学报(医学版), 2014, 52(7): 56-59. |
[9] | 赵华1,徐洋洋2,鹿向东3,徐同江1 . Ki-67、PTTG、VEGF与垂体瘤卒中的相关性[J]. 山东大学学报(医学版), 2014, 52(5): 82-85. |
[10] | 胡瑞1,郏雁飞2,郑燕2,马晓丽2,孔毅1,黎娉1,汪运山2. 缺氧对人胃癌细胞HIF-1α及DEC1表达的影响[J]. 山东大学学报(医学版), 2014, 52(4): 35-38. |
[11] | 王晓蕾1,郏雁飞2,郑燕2,刘华2,汪运山2. STAT3真核表达质粒的构建及对胃癌细胞增殖的影响[J]. 山东大学学报(医学版), 2013, 51(9): 45-49. |
[12] | 樊明德1,张源2,苗保旺1,郑鲲鹏1,李科1,王成伟1. Nod样受体热蛋白结构域相关蛋白3在人脑胶质瘤中的表达[J]. 山东大学学报(医学版), 2013, 51(4): 51-54. |
[13] | 邢海燕1,2,薛凤华3,秦晓敏4,张建平1,4. HIF-1α、VEGF和MMP-9在子宫内膜样腺癌中的表达及临床意义[J]. 山东大学学报(医学版), 2013, 51(4): 77-80. |
[14] | 王臣臣1,顾晓萌1,王妍2,黄山英3 . TFF3在胃癌、癌前病变中的表达及与血管生成的关系[J]. 山东大学学报(医学版), 2013, 51(2): 99-103. |
[15] | 刘海燕1,李陪2,高辉3,朱长军2,董智雄2. 染色体驱动蛋白KIF4A对胃癌细胞迁移和转移的影响[J]. 山东大学学报(医学版), 2013, 51(12): 25-28. |
|